Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Tanhäuserová, Veronika; Kuricová, Katarína; Pácal, Lukáš; Bartáková, Vendula; Řehořová, Jitka; Svojanovský, Jan; Olšovský, Jindřich; Bělobrádková, Jana; Kaňková, Kateřina

doi:10.1515/cclm-2012-0833

Cited by 24 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, FN3K SNPs associated significantly with typical aspects of diabetes have been described [28][29][30]. All this evidence reinforces the hypothesis that the combination of particular variants in the promoter and exon regions could turn into enhanced or reduced expression of other enzymes or regulator factors involved into deglycation.…”

Section: Discussionsupporting

confidence: 55%

“…In particular, we need to differentiate between T1DM and T2DM, as these are two distinct populations with a well known different predisposition to development of chronic complication, and therefore possibly different genetic backgrounds of key factors involved in the glycation process. Finally, as suggested by Tanhäuse-rová et al [29], if association of individual SNPs to progression of chronic complications of diabetes is weak, the combination of multiple SNPs (either related to oxidation pathways) could result in better prediction of such complications.…”

Section: Discussionmentioning

confidence: 93%

“…An association of the polymorphism in exon 6 (rs1056534) of the FN3K gene with the progression of diabetic nephropathy and cardiovascular morbidity and mortality was indeed reported [29]. Recently, Škrha and co-workers, in a cohort of 129 T1DM, 340 T2DM and 126 controls, evaluated the association of FN3K and GLO1 polymorphisms with parameters of endothelial dysfunction and soluble receptor for AGEs (sRAGE) [30].…”

Section: Genetics: Results From Presented Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients

Avemaria

Carrera

Lapolla

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Diabetes mellitus is a global pandemic and continues to increase in numbers and significance. Several pathogenic processes are involved in the development of such disease and these mechanisms could be influenced by genetic, epigenetic and environmental factors. Non-enzymatic glycation reactions of proteins have been strongly related to pathogenesis of chronic diabetic complications. The identification of fructosamine 3-kinase (FN3K), an enzyme involved in protein deglycation, a new form of protein repair, is of great interest. FN3K phosphorylates fructosamines on the third carbon of their sugar moiety, making them unstable and causing them to detach from proteins, suggesting a protective role of this enzyme. Moreover, the variability in FN3K activity has been associated with some polymorphisms in the FN3K gene. Here we argue about genetic studies and evidence of FN3K involvement in diabetes, together with results of our analysis of the FN3K gene on a Caucasian cohort of diabetic patients. Present knowledge suggests that FN3K could act in concert with other molecular mechanisms and may impact on gene expression and activity of other enzymes involved in deglycation process.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 93%

Section: Genetics: Results From Presented Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients

Avemaria

Carrera

Lapolla

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…The phosphorus in inorganic form is often combined with calcium within the skeleton, while approximately 15% as a phosphate salt exists in the blood. Circulating ALP and phosphate concentrations often increase in end-stage renal disease, and are associated with higher cardiovascular and total mortality among hemodialysis patients [1], [2]. Previous meta-analyses show that elevated serum levels of phosphorus indicate a higher risk of mortality in population with chronic kidney disease (CKD) [3], [4], with the premise that the relation between the exposure and outcome being linear.…”

Section: Introductionmentioning

confidence: 99%

Can Serum Levels of Alkaline Phosphatase and Phosphate Predict Cardiovascular Diseases and Total Mortality in Individuals with Preserved Renal Function? A Systemic Review and Meta-Analysis

Cui

Fan

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundIt is demonstrated that elevated serum levels of alkaline phosphatase (ALP) and phosphate indicate a higher risks of cardiovascular disease (CVD) and total mortality in population with chronic kidney disease (CKD), but it remains unclear whether this association exists in people with normal or preserved renal function.MethodClinical trials were searched from Embase and PubMed from inception to 2013 December using the keywords “ALP”, “phosphate”, “CVD”, “mortality” and so on, and finally 24 trials with a total of 147634 patients were included in this study. Dose-response and semi-parametric meta-analyses were performed.ResultsA linear association of serum levels of ALP and phosphate with risks of coronary heart disease (CHD) events, CVD events and deaths was identified. The relative risk(RR)of ALP for CVD deaths was 1.02 (95% confidence interval [CI], 1.01–1.04). The RR of phosphate for CVD deaths and events was 1.05 (95% CI, 1.02–1.09) and 1.04 (95% CI: 1.03–1.06), respectively. A non-linear association of ALP and phosphate with total mortality was identified. Compared with the reference category of ALP and phosphate, the pooled RR of ALP for total mortality was 1.57 (95% CI, 1.27–1.95) for the high ALP group, while the RR of phosphate for total mortality was 1.33 (95% CI, 1.21–1.46) for the high phosphate group. It was observed in subgroup analysis that higher levels of serum ALP and phosphate seemed to indicate a higher mortality rate in diabetic patients and those having previous CVD. The higher total mortality rate was more obvious in the men and Asians with high ALP.ConclusionA non-linear relationship exists between serum levels of ALP and phosphate and risk of total mortality. There appears to be a positive association of serum levels of ALP/phosphate with total mortality in people with normal or preserved renal function, while the relationship between ALP and CVD is still ambiguous.

show abstract

“…Tanhäuserová et al present an interesting analysis of genetic variability in this and other enzymes that provide protection against hyperglycemia and Maillard reaction damage to proteins in diabetes [13]. Three papers address changes in AGEs in plasma and cerebrospinal fluid in trauma [14], cerebrovascular disease [15], and Alzheimer's disease [16].…”

mentioning

confidence: 99%

Frontiers in research on the Maillard reaction in aging and chronic disease

Baynes

Gillery²

2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Abstract: Genetic variability in rate-limiting enzymes of pathways proposed to confer hypothetical protection against hyperglycemia might act as an important determinant of hyperglycemia toxicity in long-standing diabetes.

Cited by 24 publications

References 15 publications

Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients

Possible role of fructosamine 3-kinase genotyping for the management of diabetic patients

Can Serum Levels of Alkaline Phosphatase and Phosphate Predict Cardiovascular Diseases and Total Mortality in Individuals with Preserved Renal Function? A Systemic Review and Meta-Analysis

Frontiers in research on the Maillard reaction in aging and chronic disease

Contact Info

Product

Resources

About